HF/Transplantation News

Due to demographic changes and a rise in risk factors, the prevalence and economic burden of heart disease and stroke in the United States are expected to increase dramatically by 2050, according to the American Heart Association.

COVID-19 vaccination decreased the risk for CV events, hospitalization and death among patients with HF, according to a poster presented at the European Society of Cardiology’s Heart Failure 2024 meeting.

In a study of Medicare beneficiaries, researchers from Brigham and Women’s Hospital found that 6% of patients treated for heart failure progressed to dialysis within 1 year after hospitalization.

A common cardiac amyloidosis-causing gene believed to be present in around 3% of the Black U.S. population is associated with increased risk for HF hospitalization and death, which increases with age, a speaker reported.

Renin-angiotensin system blockade conferred similar mortality benefits for Black vs. non-Black patients with HF, and despite less benefit for hospitalization for Black patients, absolute benefit was comparable, researchers reported.

A single burst of antitachycardia pacing before an implantable cardioverter defibrillator shock lowered risk for all-cause shock compared with a standard shock protocol, according to the results of the APPRAISE ATP trial.

A novel lead for use in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators exceeded the safety and efficacy thresholds in the LEADR trial, researchers reported at Heart Rhythm 2024.

Most childhood cancer survivors are not up to date on guideline-recommended screening for late effects of cancer treatment or second malignancies, according to study results.

A system including a leadless pacemaker and a subcutaneous implantable cardioverter defibrillator that wirelessly communicate with each other was safe in patients at risk for fatal ventricular arrhythmias at 6 months, researchers reported.

For athletes with arrhythmias, the return-to-play decision should be individualized based on appropriate risk assessment and treatment and the shared decision-making process should be used, according to a new expert statement.